Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity
Ma, Xiao , Zhu, Ping , Zhang, Hong , Qiu, Qi , Dvornikov, Alexey V. , Wang, Zheng , Wang, Yong , Lowerison, Matthew R. , Yu, Yue , Norton, Nadine , Herrmann, Joerg , Ekker, Stephen C. , Ding, Yonghe , Zhang, Hong , Qiu, Qi , Dvornikov, Alexey V , Wang, Zheng , Kim, Maengjo , Lowerison, Matthew , Ekker, Stephen C , Lin, Xueying , Ma, Xiao , Hsiai, Tzung K. , Xu, Xiaolei , Norton, Nadine

Mayo Clinic

Science Advances | January 30, 2020 | Volume: 6 | Issue: 5 | Pages: No page available

10.1126/sciadv.aay2939 | PMID 32064346 Get It

RXRA is an endothelial- and early stage–predominant therapeutic target for treating anthracycline-induced cardiotoxicity.
Dapagliflozin restores insulin and growth hormone secretion in obese mice
Huang, Zhengxiang , Wang, Chengjian , Zhu, Shanli, Qi, Xinzhou , Chen, Yang , Veldhuis, Johannes D. , Chen, Chen , Chen, C , Huang, Lili , Zhang, Yanjun , Cowley, Michael A.

Mayo Clinic

Journal of Endocrinology | January 28, 2020 | Volume: 245 | Issue: 1 | Pages: 1-12

10.1530/joe-19-0385 | PMID 31977312 Get It

The well-documented hormonal disturbance in a general obese population is characterised by an increase in insulin secretion and a decrease in growth hormone (GH) secretion. Such hormonal disturbance promotes an increase in fat mass, which deteriorates obesity and accelerates the development of insulin resistance and type 2 diabetes. While the pathological consequence is alarming, the pharmaceutical approach attempting to correct such hormonal disturbance remains limited. By applying an emerging anti-diabetic drug, the sodium-glucose cotransporter 2 inhibitor, dapagliflozin (1 mg/kg/day for 10 weeks), to a hyperphagic obese mouse model, we observed a significant improvement in insulin and GH secretion as early as 4 weeks after the initiation of the treatment. Restoration of pathological disturbance of insulin and GH secretion reduced fat accumulation and preserved lean body mass in the obese animal model. Such phenotypic improvement followed with concurrent improvements in glucose and lipid metabolism, insulin sensitivity, as well as the expression of metabolic genes that were regulated by insulin and GH. In conclusion, 10 weeks of treatment with dapagliflozin effectively reduces hyperinsulinemia and restores pulsatile GH secretion in the hyperphagic obese mice with considerable improvement in lipid and glucose metabolism. Promising outcomes from this study may provide insights into drug intervention to correct hormonal disturbance in obesity to delay the diabetes progression.
Sex-specific impact of patterns of imageable tumor growth on survival of primary glioblastoma patients
Whitmire, Paula , Rickertsen, Cassandra , Lorence, Julia, León, Gustavo De , Bayless, Spencer, Clark-Swanson, Kamala , Corpuz, Christina, Angeles, Christine Paula Lewis-de los, Vora, Sujay A., Mrugała, Maciej M. , Hu, Leland , Porter, Alyx B. , Kumthekar, Priya , Johnston, Sandra K. , Egan, Kathleen M. , Canoll, Peter , Swanson, Kristin R. , Swanson, Kristin R , Hawkins‐Daarud, Andrea , Carrasco, Eduardo, Curtin, Lee , Peeri, Noah Charles , Bendok, Bernard R. , Gonzalez‐Cuyar, Luis F. , Wang, Lei G. , Gatenby, Robert A. , Rubin, Joshua B

Mayo Clinic

No container title available | January 27, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.10177/v4 Get It

Abstract Background : Sex is recognized as a significant determinant of outcome among glioblastoma patients, but the relative prognostic importance of glioblastoma features has not been thoroughly explored for sex differences. Methods : Combining multi-modal MR images, biomathematical models, and patient clinical information, this investigation assesses which pretreatment variables have a sex-specific impact on the survival of glioblastoma patients (299 males and 195 females). Results : Among males, tumor (T1Gd) radius was a predictor of overall survival (HR=1.027, p=0.044). Among females, higher tumor cell net invasion rate was a significant detriment to overall survival (HR=1.011, p<0.001). Female extreme survivors had significantly smaller tumors (T1Gd) (p=0.010 t-test), but tumor size was not correlated with female overall survival (p=0.955 CPH). Both male and female extreme survivors had significantly lower tumor cell net proliferation rates than other patients (M p=0.004, F p=0.001, t-test). Conclusion : Despite similar distributions of the MR imaging parameters between males and females, there was a sex-specific difference in how these parameters related to outcomes.
Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent
Risueño, Alberto, Hagner, Patrick R. , Towfic, Fadi , Fontanillo, Celia , Djebbari, Amira, Parker, Joel S. , Drew, Clifton P., Nowakowski, Grzegorz S. , Maurer, Matthew J. , Cerhan, James R. , Wei, Xin , Ren, Yan , Lee, Chung-Wein, Couto, Suzana S. , Wang, Maria , Pourdehnad, Michael , Gandhi, Anita K. , Trotter, Matthew , Maurer, Matthew , Cerhan, James R , Parker, Joel S

Mayo Clinic

Blood | January 24, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2019002414 | PMID 31977005 Get It

Diffuse large B-cell lymphoma is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. We sought to identify novel patient subgroups through an unsupervised analysis of a large public dataset of gene expression profiles from newly diagnosed de novo DLBCL patients, yielding two biologically distinct subgroups characterized by differences in the tumor microenvironment. Pathway analysis and immune deconvolution algorithms identified higher B-cell content and a strong proliferative signal in subgroup A and enriched T-cell, macrophage, and immune/inflammatory signals in subgroup B, reflecting similar biology to published DLBCL stratification research. A gene expression classifier, featuring 26 gene expression scores, was derived from the public dataset to discriminate subgroup A (classifier-negative, immune-low) and subgroup B (classifier-positive, immune-high) patients. Subsequent application to an independent series of diagnostic biopsies and replicated the subgroups with immune cell composition confirmed via immunohistochemistry. Avadomide, a CRL4CRBN E3 ubiquitin ligase modulator, demonstrated clinical activity in relapsed/refractory DLBCL patients, independent of COO subtypes. Given the immunomodulatory activity of avadomide and need for a patient selection strategy, we applied the gene expression classifier to pretreatment biopsies from relapsed/refractory DLBCL patients receiving avadomide (NCT01421524). Classifier-positive patients demonstrated an enrichment in response rate and progression-free survival of 44% and 6.2 months versus 19% and 1.6 months for classifier-negative patients (HR=0.49 [0.280, 0.86]; P=.0096). The classifier was not prognostic for R-CHOP or salvage immunochemotherapy. The classifier described here discriminates DLBCL tumors based on tumor and non-tumor composition and has potential utility to enrich for clinical response to immunomodulatory agents including avadomide.
Investigating the impact of disease and health record duration on the eMERGE algorithm for rheumatoid arthritis
Kronzer, Vanessa L. , Wang, Liwei , Davis, John M. , Sparks, Jeffrey A. , Crowson, Cynthia S. , Sparks, Jeffrey A , Kronzer, Vanessa L , Davis, John M , Liu, Hongfang

Mayo Clinic

Journal of the American Medical Informatics Association | January 24, 2020 | Volume: 27 | Issue: 4 | Pages: 601-605

10.1093/jamia/ocaa014 | PMID 32134444 Get It

Abstract Objective The study sought to determine the dependence of the Electronic Medical Records and Genomics (eMERGE) rheumatoid arthritis (RA) algorithm on both RA and electronic health record (EHR) duration. Materials and Methods Using a population-based cohort from the Mayo Clinic Biobank, we identified 497 patients with at least 1 RA diagnosis code. RA case status was manually determined using validated criteria for RA. RA duration was defined as time from first RA code to the index date of biobank enrollment. To simulate EHR duration, various years of EHR lookback were applied, starting at the index date and going backward. Model performance was determined by sensitivity, specificity, positive predictive value, negative predictive value, and area under the curve (AUC). Results The eMERGE algorithm performed well in this cohort, with overall sensitivity 53%, specificity 99%, positive predictive value 97%, negative predictive value 74%, and AUC 76%. Among patients with RA duration &lt;2 years, sensitivity and AUC were only 9% and 54%, respectively, but increased to 71% and 85% among patients with RA duration &gt;10 years. Longer EHR lookback also improved model performance up to a threshold of 10 years, in which sensitivity reached 52% and AUC 75%. However, optimal EHR lookback varied by RA duration; an EHR lookback of 3 years was best able to identify recently diagnosed RA cases. Conclusions eMERGE algorithm performance improves with longer RA duration as well as EHR duration up to 10 years, though shorter EHR lookback can improve identification of recently diagnosed RA cases.
Determining mutational burden and signature using RNA-seq from tumor-only samples
Jessen, Erik , Liu, Yuanhang , Kocher, Jean‐Pierre , Jessen, Erik , Davila, Jaime , Wang, Chen

Mayo Clinic

No container title available | January 23, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.21641/v1 Get It

Abstract Background: Traditionally, mutational burden and mutational signatures have been assessed by tumor-normal pair DNA sequencing. The requirement of having both normal and tumor samples is not always feasible from a clinical perspective, and led us to investigate the efficacy of using RNA sequencing of only the tumor sample to determine the mutational burden and signatures, and subsequently molecular cause of the cancer. The potential advantages include reducing the cost of testing, and simultaneously providing information on the gene expression profile and gene fusions present in the tumor.Results: In this study, we devised supervised and unsupervised learning methods to determine mutational signatures from tumor RNA-seq data. As applications, we applied the methods to a training set of 587 TCGA uterine cancer RNAseq samples, and examined in an independent testing set of xxx TCGA colorectal cancer RNAseq samples. Both diseases are known associated with microsatellite instable high (MSI-H) and driver defects in DNA polymerase ɛ (POLɛ). From RNAseq called variants, we found majority (>95%) are likely germline variants, leading to C>T enriched germline variants (dbSNP) widely applicable in tumor and normal RNAseq samples. We found significant associations between RNA-derived mutational burdens and MSI/POLɛ status, and insignificant relationship between RNAseq total coverage and derived mutational burdens. Additionally we found that over 80% of variants could be explained by using the COSMIC mutational signature-5, -6 and -10, which are implicated in natural aging, MSI-H, and POLɛ, respectively. For classifying tumor type, within UCEC we achieved a recall of 0.56 and 0.78, and specificity of 0.66 and 0.99 for MSI and POLɛ respectively. By applying learnt RNA signatures from UCEC to COAD, we were able to improve our classification of both MSI and POLɛ. Conclusions: Taken together, our work provides a novel method to detect RNAseq derived mutational signatures with effective procedures to remove likely germline variants. It can leads to accurate classification of underlying driving mechanisms of DNA damage deficiency.
Transplanting cells from old but not young donors causes physical dysfunction in older recipients
Wang, Binsheng , Liu, Zukai , Chen, Vicky P., Wang, Lichao , Inman, Christina L., Zhou, Yueying, Rowe, David W. , Kuchel, George A. , Robson, Paul , Kirkland, James L. , Xu, Ming , Guo, Chun , Xu, Ming , Kuchel, George A , Robson, Paul , Tchkonia, Tamar

Mayo Clinic

Aging Cell | January 23, 2020 | Volume: 19 | Issue: 3 | Pages: No page available

10.1111/acel.13106 | PMID 31971661 Get It

AbstractAdipose‐derived mesenchymal stem cell (ADSC)‐based regenerative therapies have shown potential for use in many chronic diseases. Aging diminishes stem cell regenerative potential, yet it is unknown whether stem cells from aged donors cause adverse effects in recipients. ADSCs can be obtained using minimally invasive approaches and possess low immunogenicity. Nevertheless, we found that transplanting ADSCs from old donors, but not those from young donors, induces physical dysfunction in older recipient mice. Using single‐cell transcriptomic analysis, we identified a naturally occurring senescent cell‐like population in ADSCs primarily from old donors that resembles in vitro‐generated senescent cells with regard to a number of key pathways. Our study reveals a previously unrecognized health concern due to ADSCs from old donors and lays the foundation for a new avenue of research to devise interventions to reduce harmful effects of ADSCs from old donors.
Induction and prevention of gastric cancer with combined Helicobacter pylori and capsaicin administration and DFMO treatment, respectively
Xin, Mingxia, Gao, Yunfeng , Monts, Josh , Monson, Kjersten, Wang, Qiushi , Bode, Ann M. , dong, zigang , Dong, Zigang , Aziz, Faisal , dong, zigang

Mayo Clinic

No container title available | January 22, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.2.21633/v1 Get It

Abstract Background: Gastric cancer risk evolves over time due to environmental, dietary, and lifestyle changes including Helicobacter pylori (H. pylori) infection and consumption of hot peppers (i.e. capsaicin). H. pylori infection promotes gastric mucosal injury in the early phase of capsaicin exposure. In addition, capsaicin consumption is reported to suppress immune function and increase host susceptibility to microbial infection. This relationship suggests a need to investigate the mechanism of how both H. pylori infection and capsaicin contribute to gastric inflammation and lead to gastric cancer. No previous experimental animal models have been developed to study this dual association. Here we developed a series of mouse models that progress from chronic gastritis to gastric cancer. C57-Balb/c mice were infected with the H. pylori (SS1) strain and then fed capsaicin (0.05% or 0.2g/kg/day) or not. Consequently, we investigated the association between H. pylori infection and capsaicin consumption during the initiation of gastric inflammation and the later development of gastric cancer. Tumor size and phenotype were analyzed to determine the molecular mechanism driving the shift from gastritis to stomach cancer. Gastric carcinogenesis was also prevented in these models using the ornithine decarboxylase inhibitor DFMO (2-difluoromethylornithine). Results: This study provides evidence showing that a combination of H. pylori infection and capsaicin consumption leads to gastric carcinogenesis. The transition from chronic gastritis to gastric cancer is mediated through interleukin-6 (IL-6) stimulation with an incidence rate of 50%. However, this progression can be prevented by treating with anti-inflammatory agents. In particular, we used DFMO to prevent gastric tumorigenesis by reducing inflammation and promoting recovery of disease-free stasis. The anti-inflammatory role of DFMO highlights the injurious effect of inflammation in gastric cancer development and the need to reduce gastric inflammation for cancer prevention. Conclusions: Overall, these mouse models provide reliable systems for analyzing the molecular mechanisms and synergistic effects of H. pylori and capsaicin on human cancer etiology. Accordingly, preventive measures like reduced capsaicin consumption, H. pylori clearance, and DFMO treatment can lessen gastric cancer incidence. Lastly, anti-inflammatory agents like DFMO can play important roles in prevention of inflammation-associated gastric cancer.
Controlled aliasing for improved parallel imaging with a 3D spiral staircase trajectory
Anderson, Ashley G. , Wang, Dinghui , Pipe, James G. , Anderson, Ashley G.

Mayo Clinic

Magnetic Resonance in Medicine | January 22, 2020 | Volume: 84 | Issue: 2 | Pages: 866-872

10.1002/mrm.28154 | PMID 31967342 Get It

PurposeTo introduce a modified 3D stack‐of‐spirals trajectory and efficient SENSE reconstruction for improved through‐plane undersampling, while maintaining SNR efficiency and other benefits of spiral acquisitions.MethodsA novel spiral staircase trajectory is introduced. This trajectory is a modified stack of spirals, in which spiral arms are distributed between partitions along kz. The trajectory maintains the efficient separable reconstruction with a Cartesian fast Fourier transform along the kz direction, followed by a 2D slice‐by‐slice gridding reconstruction. An additional intermediate step introduces a phase correction to collapse the spiral arms into the prescribed slice planes. For data undersampled through plane, this produces aliasing with reduced coherence, controlled by the arm‐ordering. Undersampled data can then be reconstructed with reduced g‐factor using a conjugate gradient–based iterative SENSE algorithm.ResultsThe trajectory significantly improves g‐factor for through‐plane accelerated acquisitions. Improvement manifests through both reduced overall g‐factor and reduced structure in the g‐factor maps. In the presented experiments, the mean g‐factor decreased from 1.26 to 0.93 and the maximum g‐factor decreased from 3.89 to 1.15 for R = 2 spiral staircase when compared with stack of spirals, and the mean g‐factor decreased from 2.51 to 0.94 and the maximum g‐factor decreased from 8.26 to 1.35 for R = 3 spiral staircase when compared with stack of spirals.ConclusionThe novel spiral staircase trajectory offers improved aliasing characteristics for through‐plane parallel imaging acceleration in 3D spiral acquisitions.